Results 121 to 130 of about 8,075,360 (336)
Do Broth Culture Filtrates Contain a Bacterial Growth-Inhibiting Substance? [PDF]
L. A. Barnes
openalex +1 more source
T. Tien, M. H. Gaskins, D. Hubbell
semanticscholar +1 more source
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source
Immunological Demonstration of a Substance in Rat Blood Associated with Tissue Growth
D. A. DARCY
openalex +1 more source
THE EFFECT OF THE INTRAVENOUS INJECTION OF SUBSTANCES AFFECTING TUMOR GROWTH ON THE CYCLIC CHANGES IN THE OVARIES AND ON PLACENTOMATA [PDF]
Moyer S. Fleisher, Leo Loeb
openalex +1 more source
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner +6 more
wiley +1 more source
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
IMMUNIZATION AGAINST THE ACTION OF SUBSTANCES INHIBITING TUMOR GROWTH [PDF]
Moyer S. Fleisher +2 more
openalex +1 more source
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source

